BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
BioVersys AG has entered into a collaboration and license agreement with Hackensack Meridian Health to strengthen its ansamycin platform and research on non-tuberculous mycobacteria (NTM). The agreement includes an exclusive ansamycin drug discovery collaboration and eligibility for Hackensack Meridian Health to receive upfront and near-term payments as well as royalties on future sales.
BioVersys AG, a clinical stage biopharmaceutical company, has announced a collaboration with Hackensack Meridian Health. The partnership aims to develop ansamycin candidates for serious life-threatening infections caused by multi-drug resistant bacteria. BioVersys will jointly profile and develop ansamycin candidates with Hackensack Meridian Health. The agreement includes payments and royalties for Hackensack Meridian Health. This collaboration strengthens BioVersys' ansamycin platform and NTM research.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.